| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Colorectal Neoplasms | 6 | 2023 | 47 | 3.010 |
Why?
|
| MicroRNAs | 3 | 2023 | 32 | 1.690 |
Why?
|
| Islets of Langerhans | 6 | 2003 | 10 | 0.970 |
Why?
|
| Apoptosis | 4 | 2023 | 39 | 0.870 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2023 | 20 | 0.870 |
Why?
|
| DNA Damage | 2 | 2021 | 12 | 0.780 |
Why?
|
| Microsatellite Instability | 2 | 2022 | 5 | 0.740 |
Why?
|
| Lung | 1 | 2020 | 70 | 0.710 |
Why?
|
| Lopinavir | 1 | 2020 | 137 | 0.700 |
Why?
|
| Cytoplasm | 1 | 2020 | 7 | 0.700 |
Why?
|
| Ritonavir | 1 | 2020 | 137 | 0.700 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2020 | 9 | 0.700 |
Why?
|
| HIV Protease Inhibitors | 1 | 2020 | 92 | 0.700 |
Why?
|
| Viral Core Proteins | 1 | 2020 | 10 | 0.700 |
Why?
|
| Hepatitis B Core Antigens | 1 | 2020 | 10 | 0.700 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2019 | 3 | 0.690 |
Why?
|
| Biomarkers, Tumor | 1 | 2019 | 25 | 0.640 |
Why?
|
| Humans | 28 | 2023 | 14077 | 0.590 |
Why?
|
| Hepatitis B virus | 1 | 2020 | 155 | 0.590 |
Why?
|
| Receptors, Laminin | 5 | 2016 | 6 | 0.580 |
Why?
|
| Antiretroviral Therapy, Highly Active | 2 | 2020 | 468 | 0.580 |
Why?
|
| Cell Line, Tumor | 6 | 2023 | 70 | 0.550 |
Why?
|
| Cathepsins | 1 | 2016 | 1 | 0.530 |
Why?
|
| Nucleosides | 1 | 2015 | 3 | 0.520 |
Why?
|
| Uterus | 3 | 2013 | 20 | 0.490 |
Why?
|
| Medication Adherence | 1 | 2016 | 137 | 0.480 |
Why?
|
| Animals | 16 | 2023 | 1063 | 0.460 |
Why?
|
| Cell Line | 5 | 2020 | 92 | 0.430 |
Why?
|
| Tretinoin | 3 | 2003 | 8 | 0.420 |
Why?
|
| Antineoplastic Agents | 4 | 2023 | 61 | 0.380 |
Why?
|
| Aurora Kinase B | 2 | 2021 | 2 | 0.380 |
Why?
|
| Mad2 Proteins | 2 | 2021 | 2 | 0.380 |
Why?
|
| Neoplasms | 3 | 2023 | 141 | 0.370 |
Why?
|
| Cell Differentiation | 7 | 2014 | 20 | 0.370 |
Why?
|
| Amyloid beta-Peptides | 3 | 2016 | 22 | 0.350 |
Why?
|
| Amelogenin | 1 | 2008 | 3 | 0.330 |
Why?
|
| Sex Determination by Skeleton | 1 | 2008 | 3 | 0.330 |
Why?
|
| Sex Determination Analysis | 1 | 2008 | 5 | 0.330 |
Why?
|
| Polymers | 2 | 2011 | 133 | 0.320 |
Why?
|
| Caspase 3 | 2 | 2020 | 3 | 0.320 |
Why?
|
| Alkaline Phosphatase | 4 | 2014 | 18 | 0.310 |
Why?
|
| Adipocytes | 4 | 2014 | 23 | 0.310 |
Why?
|
| Zinc Sulfate | 1 | 2008 | 6 | 0.310 |
Why?
|
| Insulin | 5 | 2006 | 72 | 0.310 |
Why?
|
| Cross-Linking Reagents | 1 | 2008 | 33 | 0.310 |
Why?
|
| Technology, Pharmaceutical | 1 | 2008 | 35 | 0.310 |
Why?
|
| Mifepristone | 3 | 2014 | 7 | 0.310 |
Why?
|
| Drug Combinations | 3 | 2020 | 41 | 0.310 |
Why?
|
| Clomiphene | 1 | 2008 | 1 | 0.310 |
Why?
|
| Microfilament Proteins | 1 | 2008 | 1 | 0.310 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2008 | 1 | 0.310 |
Why?
|
| Drug Carriers | 1 | 2008 | 93 | 0.300 |
Why?
|
| Antibodies, Monoclonal | 3 | 2013 | 137 | 0.300 |
Why?
|
| Isoniazid | 1 | 2008 | 110 | 0.290 |
Why?
|
| Protein Transport | 5 | 2020 | 7 | 0.290 |
Why?
|
| Rifampin | 1 | 2008 | 189 | 0.280 |
Why?
|
| Pancreas | 3 | 2003 | 5 | 0.280 |
Why?
|
| Absorbable Implants | 2 | 2018 | 8 | 0.260 |
Why?
|
| Cell Count | 2 | 2002 | 10 | 0.260 |
Why?
|
| Apoptosis Regulatory Proteins | 2 | 2023 | 4 | 0.250 |
Why?
|
| Antitubercular Agents | 1 | 2008 | 299 | 0.250 |
Why?
|
| Chick Embryo | 5 | 2002 | 8 | 0.240 |
Why?
|
| Mesoderm | 2 | 2002 | 2 | 0.240 |
Why?
|
| Gene Expression Regulation, Developmental | 2 | 2014 | 2 | 0.230 |
Why?
|
| Embryo Implantation | 2 | 2014 | 3 | 0.230 |
Why?
|
| Colonic Neoplasms | 1 | 2023 | 7 | 0.230 |
Why?
|
| DNA Demethylation | 1 | 2023 | 1 | 0.230 |
Why?
|
| Hydroxamic Acids | 1 | 2023 | 2 | 0.230 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2023 | 3 | 0.230 |
Why?
|
| Histones | 1 | 2023 | 7 | 0.230 |
Why?
|
| DNA Methylation | 1 | 2023 | 19 | 0.220 |
Why?
|
| Alzheimer Disease | 2 | 2014 | 30 | 0.220 |
Why?
|
| Epigenesis, Genetic | 1 | 2023 | 17 | 0.220 |
Why?
|
| Mesothelioma | 1 | 2023 | 4 | 0.220 |
Why?
|
| Cancer-Associated Fibroblasts | 1 | 2023 | 1 | 0.220 |
Why?
|
| Female | 9 | 2019 | 8751 | 0.210 |
Why?
|
| Curcumin | 1 | 2023 | 13 | 0.210 |
Why?
|
| RNA, Small Interfering | 2 | 2013 | 49 | 0.210 |
Why?
|
| Activins | 1 | 2002 | 3 | 0.200 |
Why?
|
| Cell Division | 2 | 2003 | 12 | 0.200 |
Why?
|
| Progesterone | 2 | 2014 | 5 | 0.200 |
Why?
|
| Growth Substances | 1 | 2001 | 1 | 0.190 |
Why?
|
| Body Patterning | 1 | 2001 | 1 | 0.190 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2001 | 5 | 0.190 |
Why?
|
| A549 Cells | 1 | 2020 | 3 | 0.190 |
Why?
|
| Mutagenicity Tests | 1 | 2020 | 3 | 0.190 |
Why?
|
| Fibroblasts | 1 | 2020 | 14 | 0.180 |
Why?
|
| Microscopy, Confocal | 1 | 2020 | 3 | 0.180 |
Why?
|
| Protein Precursors | 1 | 2020 | 22 | 0.170 |
Why?
|
| Mice | 6 | 2023 | 134 | 0.170 |
Why?
|
| South Africa | 6 | 2022 | 7312 | 0.170 |
Why?
|
| Geography | 1 | 2019 | 60 | 0.170 |
Why?
|
| Male | 4 | 2022 | 6489 | 0.170 |
Why?
|
| Gene Regulatory Networks | 1 | 2019 | 7 | 0.160 |
Why?
|
| Cells, Cultured | 4 | 2013 | 79 | 0.160 |
Why?
|
| Antineoplastic Protocols | 1 | 2018 | 4 | 0.160 |
Why?
|
| Logistic Models | 1 | 2019 | 252 | 0.160 |
Why?
|
| Carcinoma | 1 | 2018 | 9 | 0.160 |
Why?
|
| Ovarian Neoplasms | 1 | 2018 | 15 | 0.160 |
Why?
|
| Cell Proliferation | 3 | 2023 | 43 | 0.160 |
Why?
|
| Endometrium | 2 | 2014 | 3 | 0.150 |
Why?
|
| Amyloid beta-Protein Precursor | 2 | 2014 | 2 | 0.150 |
Why?
|
| Amyloid Precursor Protein Secretases | 2 | 2014 | 2 | 0.150 |
Why?
|
| HIV Infections | 1 | 2016 | 4946 | 0.150 |
Why?
|
| Incidence | 1 | 2019 | 655 | 0.150 |
Why?
|
| Nanoparticles | 2 | 2018 | 104 | 0.140 |
Why?
|
| Signal Transduction | 2 | 2014 | 33 | 0.140 |
Why?
|
| Rats, Wistar | 3 | 2014 | 13 | 0.130 |
Why?
|
| Rats | 4 | 2013 | 130 | 0.130 |
Why?
|
| Prions | 1 | 2016 | 1 | 0.130 |
Why?
|
| Cysteine | 1 | 2016 | 3 | 0.130 |
Why?
|
| Electrophoresis | 1 | 2016 | 3 | 0.130 |
Why?
|
| Peptide Fragments | 1 | 2016 | 36 | 0.130 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2016 | 60 | 0.130 |
Why?
|
| Antibodies | 1 | 2016 | 25 | 0.130 |
Why?
|
| HT29 Cells | 1 | 2015 | 1 | 0.130 |
Why?
|
| Caspase 8 | 1 | 2015 | 2 | 0.130 |
Why?
|
| Annexin A5 | 1 | 2015 | 2 | 0.130 |
Why?
|
| Membrane Potential, Mitochondrial | 1 | 2015 | 7 | 0.130 |
Why?
|
| Caco-2 Cells | 1 | 2015 | 10 | 0.130 |
Why?
|
| Camptothecin | 1 | 2015 | 8 | 0.130 |
Why?
|
| Mitochondria | 1 | 2015 | 12 | 0.130 |
Why?
|
| Immunohistochemistry | 2 | 2008 | 26 | 0.130 |
Why?
|
| Lipid Metabolism | 4 | 2014 | 44 | 0.130 |
Why?
|
| Molecular Imaging | 1 | 2014 | 3 | 0.120 |
Why?
|
| Contraceptives, Postcoital, Synthetic | 1 | 2014 | 1 | 0.120 |
Why?
|
| Cost-Benefit Analysis | 1 | 2016 | 235 | 0.120 |
Why?
|
| Receptors, Progesterone | 1 | 2014 | 14 | 0.120 |
Why?
|
| Biosensing Techniques | 1 | 2014 | 6 | 0.120 |
Why?
|
| Diagnostic Imaging | 1 | 2014 | 9 | 0.120 |
Why?
|
| Middle Aged | 2 | 2019 | 3425 | 0.120 |
Why?
|
| Nanomedicine | 1 | 2014 | 23 | 0.110 |
Why?
|
| Neovascularization, Physiologic | 1 | 2013 | 1 | 0.110 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2013 | 3 | 0.110 |
Why?
|
| Glucagon | 3 | 2003 | 4 | 0.100 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2023 | 7 | 0.100 |
Why?
|
| Viral Load | 1 | 2016 | 808 | 0.100 |
Why?
|
| Base Sequence | 2 | 2008 | 149 | 0.090 |
Why?
|
| Obesity | 1 | 2014 | 356 | 0.090 |
Why?
|
| Adult | 4 | 2016 | 5664 | 0.090 |
Why?
|
| Molecular Sequence Data | 2 | 2008 | 263 | 0.090 |
Why?
|
| Culture Media, Serum-Free | 2 | 2001 | 2 | 0.090 |
Why?
|
| Osteoarthritis | 1 | 2010 | 4 | 0.090 |
Why?
|
| bcl-2-Associated X Protein | 2 | 2023 | 3 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2023 | 5 | 0.090 |
Why?
|
| Femur | 1 | 2009 | 11 | 0.080 |
Why?
|
| DNA | 1 | 2009 | 73 | 0.080 |
Why?
|
| Protein Binding | 3 | 2014 | 62 | 0.080 |
Why?
|
| Paleontology | 1 | 2008 | 3 | 0.080 |
Why?
|
| Chromosomes, Human, X | 1 | 2008 | 3 | 0.080 |
Why?
|
| Forensic Genetics | 1 | 2008 | 3 | 0.080 |
Why?
|
| Chromosomes, Human, Y | 1 | 2008 | 9 | 0.080 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 2008 | 16 | 0.080 |
Why?
|
| Cell Membrane | 3 | 2013 | 10 | 0.080 |
Why?
|
| Histidine | 4 | 2014 | 9 | 0.080 |
Why?
|
| Bone and Bones | 1 | 2008 | 38 | 0.080 |
Why?
|
| Specimen Handling | 1 | 2009 | 103 | 0.080 |
Why?
|
| Plasticizers | 1 | 2008 | 4 | 0.080 |
Why?
|
| Citrates | 1 | 2008 | 4 | 0.080 |
Why?
|
| Spectrophotometry, Ultraviolet | 1 | 2008 | 6 | 0.080 |
Why?
|
| Least-Squares Analysis | 1 | 2008 | 5 | 0.080 |
Why?
|
| Temperature | 2 | 2009 | 56 | 0.080 |
Why?
|
| Gastric Juice | 1 | 2008 | 6 | 0.080 |
Why?
|
| Models, Chemical | 1 | 2008 | 13 | 0.080 |
Why?
|
| Solubility | 1 | 2008 | 51 | 0.080 |
Why?
|
| Surface Properties | 1 | 2008 | 46 | 0.080 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2008 | 61 | 0.080 |
Why?
|
| Kinetics | 1 | 2008 | 65 | 0.080 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2008 | 76 | 0.080 |
Why?
|
| Actinin | 1 | 2008 | 1 | 0.080 |
Why?
|
| Ovariectomy | 1 | 2008 | 1 | 0.080 |
Why?
|
| Vinculin | 1 | 2008 | 1 | 0.080 |
Why?
|
| Gelsolin | 1 | 2008 | 1 | 0.080 |
Why?
|
| Epithelium | 1 | 2008 | 8 | 0.080 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 2 | 2014 | 5 | 0.080 |
Why?
|
| Contraceptives, Postcoital | 1 | 2008 | 3 | 0.080 |
Why?
|
| Administration, Oral | 1 | 2008 | 113 | 0.080 |
Why?
|
| Estradiol | 1 | 2008 | 18 | 0.080 |
Why?
|
| Models, Statistical | 1 | 2008 | 53 | 0.080 |
Why?
|
| Gene Expression Regulation | 3 | 2016 | 40 | 0.070 |
Why?
|
| Polymerase Chain Reaction | 1 | 2008 | 260 | 0.070 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2008 | 190 | 0.070 |
Why?
|
| HIV-1 | 1 | 2016 | 1239 | 0.070 |
Why?
|
| Mammary Glands, Human | 1 | 2006 | 2 | 0.070 |
Why?
|
| Enzyme Inhibitors | 1 | 2006 | 22 | 0.070 |
Why?
|
| Adipose Tissue | 1 | 2006 | 51 | 0.070 |
Why?
|
| Lipids | 1 | 2006 | 81 | 0.070 |
Why?
|
| Blood Preservation | 1 | 2004 | 3 | 0.060 |
Why?
|
| Plasma | 1 | 2004 | 39 | 0.060 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2023 | 2 | 0.060 |
Why?
|
| Carcinogenesis | 1 | 2023 | 4 | 0.060 |
Why?
|
| Phenols | 1 | 2023 | 4 | 0.060 |
Why?
|
| ErbB Receptors | 1 | 2023 | 14 | 0.060 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2023 | 1 | 0.060 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2023 | 7 | 0.060 |
Why?
|
| CTLA-4 Antigen | 1 | 2023 | 5 | 0.050 |
Why?
|
| Dendritic Cells | 1 | 2023 | 4 | 0.050 |
Why?
|
| Microsatellite Repeats | 1 | 2022 | 14 | 0.050 |
Why?
|
| Chickens | 1 | 2002 | 5 | 0.050 |
Why?
|
| Pregnancy | 3 | 2014 | 1815 | 0.050 |
Why?
|
| Cytokines | 1 | 2023 | 107 | 0.050 |
Why?
|
| Cell Culture Techniques | 1 | 2002 | 7 | 0.050 |
Why?
|
| K562 Cells | 1 | 2021 | 1 | 0.050 |
Why?
|
| Imidazoles | 1 | 2021 | 9 | 0.050 |
Why?
|
| 3T3-L1 Cells | 3 | 2006 | 10 | 0.050 |
Why?
|
| Pyridines | 1 | 2021 | 10 | 0.050 |
Why?
|
| Adipogenesis | 2 | 2014 | 9 | 0.050 |
Why?
|
| Stem Cells | 1 | 2001 | 1 | 0.050 |
Why?
|
| Stem Cell Transplantation | 1 | 2001 | 2 | 0.050 |
Why?
|
| Retrospective Studies | 1 | 2022 | 767 | 0.040 |
Why?
|
| Diabetes Mellitus | 1 | 2001 | 137 | 0.040 |
Why?
|
| Acrylamides | 1 | 2018 | 3 | 0.040 |
Why?
|
| Povidone | 1 | 2018 | 3 | 0.040 |
Why?
|
| Mice, Nude | 1 | 2018 | 12 | 0.040 |
Why?
|
| Micelles | 1 | 2018 | 6 | 0.040 |
Why?
|
| Methotrexate | 1 | 2018 | 17 | 0.040 |
Why?
|
| Hydrogels | 1 | 2018 | 42 | 0.040 |
Why?
|
| Chitosan | 1 | 2018 | 46 | 0.040 |
Why?
|
| Cell Line, Transformed | 1 | 2016 | 6 | 0.030 |
Why?
|
| Ribosomal Proteins | 1 | 2016 | 3 | 0.030 |
Why?
|
| Transfection | 1 | 2016 | 29 | 0.030 |
Why?
|
| Cell Survival | 1 | 2016 | 45 | 0.030 |
Why?
|
| Levamisole | 2 | 2006 | 6 | 0.030 |
Why?
|
| Culture Media | 2 | 2006 | 15 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2016 | 65 | 0.030 |
Why?
|
| Primary Cell Culture | 1 | 2014 | 4 | 0.030 |
Why?
|
| Azo Compounds | 1 | 2014 | 6 | 0.030 |
Why?
|
| Genes, Reporter | 1 | 2014 | 12 | 0.030 |
Why?
|
| Estrogen Receptor Antagonists | 1 | 2014 | 1 | 0.030 |
Why?
|
| Injections, Subcutaneous | 1 | 2014 | 22 | 0.030 |
Why?
|
| Trypan Blue | 1 | 2013 | 1 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2013 | 6 | 0.030 |
Why?
|
| DNA Primers | 1 | 2013 | 55 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2013 | 64 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2013 | 77 | 0.030 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2013 | 1 | 0.030 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2013 | 3 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2013 | 14 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2013 | 90 | 0.030 |
Why?
|
| Intracellular Space | 1 | 2013 | 1 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2013 | 4 | 0.030 |
Why?
|
| Down-Regulation | 1 | 2013 | 22 | 0.030 |
Why?
|
| Time Factors | 2 | 2005 | 503 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2014 | 312 | 0.030 |
Why?
|
| RNA Interference | 1 | 2013 | 45 | 0.030 |
Why?
|
| Prevalence | 1 | 2014 | 1149 | 0.020 |
Why?
|
| Osteoarthritis, Hip | 1 | 2010 | 1 | 0.020 |
Why?
|
| Isotope Labeling | 1 | 2010 | 2 | 0.020 |
Why?
|
| Osteochondrodysplasias | 1 | 2010 | 2 | 0.020 |
Why?
|
| Epigenomics | 1 | 2010 | 3 | 0.020 |
Why?
|
| Endemic Diseases | 1 | 2010 | 15 | 0.020 |
Why?
|
| Radiography | 1 | 2010 | 80 | 0.020 |
Why?
|
| Diet | 1 | 2010 | 108 | 0.020 |
Why?
|
| Cell Polarity | 1 | 2008 | 1 | 0.020 |
Why?
|
| Cell Surface Extensions | 1 | 2008 | 1 | 0.020 |
Why?
|
| Microvilli | 1 | 2008 | 2 | 0.020 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 2008 | 34 | 0.020 |
Why?
|
| Epithelial Cells | 1 | 2008 | 14 | 0.020 |
Why?
|
| 1-Methyl-3-isobutylxanthine | 1 | 2006 | 3 | 0.020 |
Why?
|
| Intracellular Fluid | 1 | 2006 | 3 | 0.020 |
Why?
|
| Dexamethasone | 1 | 2006 | 13 | 0.020 |
Why?
|
| Oligopeptides | 1 | 2006 | 16 | 0.020 |
Why?
|
| Sequence Alignment | 1 | 2005 | 59 | 0.020 |
Why?
|
| Dimerization | 1 | 2004 | 4 | 0.010 |
Why?
|
| Partial Thromboplastin Time | 1 | 2004 | 13 | 0.010 |
Why?
|
| Fibrinogen | 1 | 2004 | 10 | 0.010 |
Why?
|
| Thromboplastin | 1 | 2004 | 9 | 0.010 |
Why?
|
| Platelet Aggregation | 1 | 2004 | 12 | 0.010 |
Why?
|
| Prothrombin Time | 1 | 2004 | 15 | 0.010 |
Why?
|
| Freezing | 1 | 2004 | 6 | 0.010 |
Why?
|
| Bromodeoxyuridine | 1 | 2003 | 1 | 0.010 |
Why?
|
| Pancreatic Ducts | 1 | 2003 | 3 | 0.010 |
Why?
|
| Embryonic and Fetal Development | 1 | 2003 | 4 | 0.010 |
Why?
|
| Organ Culture Techniques | 1 | 2003 | 6 | 0.010 |
Why?
|